End-of-day quote
Shenzhen S.E.
06:00:00 2024-06-06 pm EDT
|
5-day change
|
1st Jan Change
|
15.2
CNY
|
+1.67%
|
|
-7.32%
|
-30.11%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9,026
|
8,316
|
6,264
|
Enterprise Value (EV)
1 |
7,167
|
6,361
|
4,447
|
P/E ratio
|
55.3
x
|
66.6
x
|
35.7
x
|
Yield
|
0.8%
|
1.15%
|
2.21%
|
Capitalization / Revenue
|
16.7
x
|
16.2
x
|
9.45
x
|
EV / Revenue
|
13.3
x
|
12.4
x
|
6.71
x
|
EV / EBITDA
|
52.1
x
|
66.5
x
|
26.8
x
|
EV / FCF
|
111
x
|
62.2
x
|
-37.4
x
|
FCF Yield
|
0.9%
|
1.61%
|
-2.67%
|
Price to Book
|
4.06
x
|
3.65
x
|
2.66
x
|
Nbr of stocks (in thousands)
|
288,000
|
288,000
|
288,000
|
Reference price
2 |
31.34
|
28.87
|
21.75
|
Announcement Date
|
4/27/22
|
4/24/23
|
4/22/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
517.1
|
660
|
592.9
|
540.6
|
514.9
|
663
|
EBITDA
1 |
127.9
|
236.8
|
218.3
|
137.4
|
95.73
|
165.6
|
EBIT
1 |
111.9
|
215.1
|
200.1
|
118.1
|
75.35
|
145.4
|
Operating Margin
|
21.64%
|
32.59%
|
33.75%
|
21.84%
|
14.63%
|
21.93%
|
Earnings before Tax (EBT)
1 |
106.6
|
217
|
198.6
|
139.2
|
147.4
|
202.8
|
Net income
1 |
47.74
|
100.3
|
168.1
|
121.6
|
125.7
|
176.1
|
Net margin
|
9.23%
|
15.19%
|
28.35%
|
22.5%
|
24.42%
|
26.56%
|
EPS
2 |
0.2250
|
0.4667
|
0.7750
|
0.5667
|
0.4333
|
0.6100
|
Free Cash Flow
1 |
8.4
|
374
|
-39.94
|
64.84
|
102.2
|
-118.8
|
FCF margin
|
1.62%
|
56.67%
|
-6.74%
|
11.99%
|
19.85%
|
-17.92%
|
FCF Conversion (EBITDA)
|
6.57%
|
157.93%
|
-
|
47.18%
|
106.77%
|
-
|
FCF Conversion (Net income)
|
17.6%
|
372.95%
|
-
|
53.3%
|
81.29%
|
-
|
Dividend per Share
|
-
|
-
|
-
|
0.2500
|
0.3333
|
0.4800
|
Announcement Date
|
6/1/21
|
6/1/21
|
6/1/21
|
4/27/22
|
4/24/23
|
4/22/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
17.9
|
343
|
346
|
1,860
|
1,955
|
1,817
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
8.4
|
374
|
-39.9
|
64.8
|
102
|
-119
|
ROE (net income / shareholders' equity)
|
25.9%
|
41.6%
|
28.3%
|
8.32%
|
5.59%
|
7.6%
|
ROA (Net income/ Total Assets)
|
11.9%
|
19.4%
|
16.1%
|
4.71%
|
1.95%
|
3.6%
|
Assets
1 |
401.1
|
517
|
1,041
|
2,583
|
6,445
|
4,889
|
Book Value Per Share
2 |
1.350
|
2.260
|
3.240
|
7.720
|
7.900
|
8.180
|
Cash Flow per Share
2 |
0.3000
|
0.3300
|
0.4900
|
6.460
|
6.450
|
5.880
|
Capex
1 |
25.1
|
32.3
|
13.4
|
21.1
|
76
|
187
|
Capex / Sales
|
4.85%
|
4.9%
|
2.26%
|
3.9%
|
14.75%
|
28.13%
|
Announcement Date
|
6/1/21
|
6/1/21
|
6/1/21
|
4/27/22
|
4/24/23
|
4/22/24
|
|
1st Jan change
|
Capi.
|
---|
| -30.11% | 604M | | +45.82% | 765B | | +40.95% | 632B | | -6.16% | 354B | | +19.86% | 331B | | +9.32% | 299B | | +18.45% | 248B | | +11.88% | 216B | | -0.78% | 219B | | +5.90% | 164B |
Other Pharmaceuticals
|